Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas

Cancer Letters

Volumn 146, Issue 2, 1999, Pages 195-199

  Schöndorf, Thomas ^a   Scharl, Anton ^a,b   Kurbacher, Christian M ^a   Bien, Odette ^a   Becker, Martina ^a   Neumann, Rainer ^c   Kolhagen, Hannelore ^a   Rustemeyer, Josi ^a   Mallmann, Peter ^a   Göhring, Uwe Jochen ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c BAYER AG   (Germany)

Author keywords

ATP tumor chemosensitivity assay; mdr1; Multidrug resistance; Ovarian carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TOPOTECAN; TREOSULFAN;

ARTICLE; CANCER RECURRENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN;

EID: 0344631759     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00263-3     Document Type: Article

References (20)

1. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40:1997;S13-S19.
2. Sarkadi B., Müller M. Search for specific inhibitors of multidrug resistance in cancer. Semin. Cancer Biol. 8:1997;171-182.
3. Bellamy W.T. P-Glycoproteins and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 36:1996;161-183.
4. Goldstein L.J. MDR1 gene expression in solid tumours. Eur. J. Cancer. 12A:1996;1039-1050.
5. Bradley G., Ling V. P-Glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13:1994;223-233.
6. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29:1995;607-649.
7. Andreotti P.E., Cree I.A., Kurbacher C.M., Hartmann D.M., Linder D., Harel G., Gleibermann I., Caruso P.A., Ricks S.H., Untch M., Sartoti C., Bruckner H.W. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55:1995;5276-5282.
8. Kurbacher C.M., Cree I.A., Bruckner H.W., Brenne U., Kurbacher J.A., Müller K., Ackermann T., Gilster T.J., Wilhelm L.M., Engel H., Mallmann P.K., Andreotti P.E. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs. 9:1998;51-57.
9. Yang X., Page M. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res. 7:1995;619-624.
10. Kavallaris M., Leary J.A., Barrett J.A., Friedlander M.L. MDR1 and multidrug resistance-associated (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 102:1996;7-16.
11. Schneider J., Centeno M., Jimenez E., Rodriguez-Escudero F.J., Romero H. Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma. Anticancer Res. 17:1997;2147-2151.
12. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
13. Moran E., Cleary I., Larkin A.M., Nic Amhlaoibh R., Masterson A., Scheper R.J., Izquierdo M.A., Center M., O'Sullivan F., Clynes M. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur. J. Cancer. 33:1997;652-660.
14. Beck J.F., Bohnet B., Brugger D., Dietl J., Scheper R.J., Bader P., Niethammer D., Gekeler V. Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res. 18:1998;701-705.
15. Masanek U., Stammler G., Volm M. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anti-Cancer Drugs. 8:1997;189-198.
16. Chao C.C., Ma C.M., Lin-Chao S. Co-amplification and over-expression of two mdr genes in a multidrug-resistant human colon carcinoma cell line. FEBS Lett. 291:1991;214-218.
17. Zhou Z., Luo X., Lin C., Chen F. The amplification and expression of MDR1 gene in adriamycin resistant cell line of colon cancer cell HR8348. Chin. Med. Sci. J. 1996;17-20.
18. Stow M.W., Warr J.R. Amplification and expression of mdr genes and flanking sequences in verapamil hypersensitive hamster cell lines. Biochim. Biophys. Acta. 1092:1991;7-14.
19. Sekiya S., Nunoyama T., Shirasawa H., Kimura H., Kawata M., Iijiama N., Sugimoto Y., Tsuruo T., Takamizawa H. Expression of a human multidrug resistance gene in human ovarian carcinoma cell lines. Arch. Gynecol. Obstet. 251:1992;79-86.
20. Nooter K., Stoter G. Molecular mechanism of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192:1996;768-780.